Which has higher earnings & valuation, JSPR or ANVS?

Annovis Bio is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jasper Therapeutics N/A N/A -$75.80M -$3.23 N/A Annovis Bio N/A N/A -$28.85M -$1.71 N/A

Is JSPR or ANVS more profitable?

Annovis Bio's return on equity of -318.08% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Jasper Therapeutics N/A -613.51% -162.52% Annovis Bio N/A -318.08% -215.47%

Which has stronger earnings & valuation, CTOR or JSPR?

Citius Oncology is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Citius Oncology N/A N/A -$24.76M -$0.47 N/A Jasper Therapeutics N/A N/A -$75.80M -$3.23 N/A

Is CTOR or JSPR more profitable?

Citius Oncology's return on equity of -99.47% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Citius Oncology N/A -99.47% -42.16% Jasper Therapeutics N/A -613.51% -162.52%

Does the media prefer CTOR or JSPR?

In the previous week, Jasper Therapeutics had 5 more articles in the media than Citius Oncology. MarketBeat recorded 6 mentions for Jasper Therapeutics and 1 mentions for Citius Oncology. Jasper Therapeutics' average media sentiment score of 0.33 beat Citius Oncology's score of 0.00 indicating that Jasper Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Citius Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Jasper Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend EXOZ or JSPR?

Jasper Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 1,398.13%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Jasper Therapeutics is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Jasper Therapeutics 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.38

Is EXOZ or JSPR more profitable?

eXoZymes' return on equity of -220.63% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets eXoZymes N/A -220.63% -141.26% Jasper Therapeutics N/A -613.51% -162.52%

Does the media favor EXOZ or JSPR?

In the previous week, Jasper Therapeutics had 5 more articles in the media than eXoZymes. MarketBeat recorded 6 mentions for Jasper Therapeutics and 1 mentions for eXoZymes. Jasper Therapeutics' average media sentiment score of 0.33 beat eXoZymes' score of 0.00 indicating that Jasper Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment eXoZymes 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Jasper Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is JSPR or IMA more profitable?

ImageneBio's return on equity of -38.96% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Jasper Therapeutics N/A -613.51% -162.52% ImageneBio N/A -38.96% -34.60%

Which has better valuation & earnings, JSPR or IMMP?

Prima BioMed has higher revenue and earnings than Jasper Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jasper Therapeutics N/A N/A -$75.80M -$3.23 N/A Prima BioMed $6.69M 8.97 -$39.78M N/A N/A

Is JSPR or IMMP more profitable?

Prima BioMed's return on equity of 0.00% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Jasper Therapeutics N/A -613.51% -162.52% Prima BioMed N/A N/A N/A

Jasper Therapeutics (JSPR) Competitors

$0.80 -0.01 (-1.61%)

As of 01:25 PM Eastern

Compare

JSPR vs. ANVS, CTOR, EXOZ, IMA, and IMMP

Should you buy Jasper Therapeutics stock or one of its competitors? MarketBeat compares Jasper Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Jasper Therapeutics include Annovis Bio (ANVS), Citius Oncology (CTOR), eXoZymes (EXOZ), ImageneBio (IMA), and Prima BioMed (IMMP). These companies are all part of the "pharmaceutical products" industry.

How does Jasper Therapeutics compare to Annovis Bio?

Jasper Therapeutics (NASDAQ:JSPR) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

Jasper Therapeutics presently has a consensus target price of $12.00, suggesting a potential upside of 1,398.13%. Annovis Bio has a consensus target price of $11.67, suggesting a potential upside of 570.50%. Given Jasper Therapeutics' higher possible upside, analysts plainly believe Jasper Therapeutics is more favorable than Annovis Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

In the previous week, Jasper Therapeutics had 6 more articles in the media than Annovis Bio. MarketBeat recorded 6 mentions for Jasper Therapeutics and 0 mentions for Annovis Bio. Jasper Therapeutics' average media sentiment score of 0.33 beat Annovis Bio's score of 0.00 indicating that Jasper Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Jasper Therapeutics	Neutral
Annovis Bio	Neutral

Annovis Bio is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jasper Therapeutics	N/A	N/A	-$75.80M	-$3.23	N/A
Annovis Bio	N/A	N/A	-$28.85M	-$1.71	N/A

Annovis Bio's return on equity of -318.08% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jasper Therapeutics	N/A	-613.51%	-162.52%
Annovis Bio	N/A	-318.08%	-215.47%

79.9% of Jasper Therapeutics shares are owned by institutional investors. Comparatively, 15.8% of Annovis Bio shares are owned by institutional investors. 2.3% of Jasper Therapeutics shares are owned by company insiders. Comparatively, 20.8% of Annovis Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Jasper Therapeutics has a beta of 3.07, indicating that its stock price is 207% more volatile than the broader market. Comparatively, Annovis Bio has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market.

Summary

Jasper Therapeutics beats Annovis Bio on 8 of the 14 factors compared between the two stocks.

How does Jasper Therapeutics compare to Citius Oncology?

Citius Oncology (NASDAQ:CTOR) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

70.5% of Citius Oncology shares are held by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are held by institutional investors. 9.8% of Citius Oncology shares are held by insiders. Comparatively, 2.3% of Jasper Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Citius Oncology is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A
Jasper Therapeutics	N/A	N/A	-$75.80M	-$3.23	N/A

In the previous week, Jasper Therapeutics had 5 more articles in the media than Citius Oncology. MarketBeat recorded 6 mentions for Jasper Therapeutics and 1 mentions for Citius Oncology. Jasper Therapeutics' average media sentiment score of 0.33 beat Citius Oncology's score of 0.00 indicating that Jasper Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Citius Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Jasper Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Citius Oncology's return on equity of -99.47% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	-99.47%	-42.16%
Jasper Therapeutics	N/A	-613.51%	-162.52%

Citius Oncology presently has a consensus price target of $6.00, suggesting a potential upside of 925.64%. Jasper Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 1,398.13%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Jasper Therapeutics is more favorable than Citius Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

Citius Oncology has a beta of 3.47, meaning that its stock price is 247% more volatile than the broader market. Comparatively, Jasper Therapeutics has a beta of 3.07, meaning that its stock price is 207% more volatile than the broader market.

Summary

Jasper Therapeutics beats Citius Oncology on 7 of the 13 factors compared between the two stocks.

How does Jasper Therapeutics compare to eXoZymes?

eXoZymes (NASDAQ:EXOZ) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Jasper Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 1,398.13%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Jasper Therapeutics is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

eXoZymes' return on equity of -220.63% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-220.63%	-141.26%
Jasper Therapeutics	N/A	-613.51%	-162.52%

eXoZymes has higher revenue and earnings than Jasper Therapeutics. eXoZymes is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	$70K	732.06	-$9.16M	-$1.14	N/A
Jasper Therapeutics	N/A	N/A	-$75.80M	-$3.23	N/A

79.9% of Jasper Therapeutics shares are owned by institutional investors. 72.4% of eXoZymes shares are owned by insiders. Comparatively, 2.3% of Jasper Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

eXoZymes has a beta of 2.73, meaning that its stock price is 173% more volatile than the broader market. Comparatively, Jasper Therapeutics has a beta of 3.07, meaning that its stock price is 207% more volatile than the broader market.

In the previous week, Jasper Therapeutics had 5 more articles in the media than eXoZymes. MarketBeat recorded 6 mentions for Jasper Therapeutics and 1 mentions for eXoZymes. Jasper Therapeutics' average media sentiment score of 0.33 beat eXoZymes' score of 0.00 indicating that Jasper Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
eXoZymes	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Jasper Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Jasper Therapeutics beats eXoZymes on 8 of the 14 factors compared between the two stocks.

How does Jasper Therapeutics compare to ImageneBio?

Jasper Therapeutics (NASDAQ:JSPR) and ImageneBio (NASDAQ:IMA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

Jasper Therapeutics currently has a consensus price target of $12.00, suggesting a potential upside of 1,398.13%. ImageneBio has a consensus price target of $26.50, suggesting a potential upside of 341.01%. Given Jasper Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Jasper Therapeutics is more favorable than ImageneBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00

ImageneBio has higher revenue and earnings than Jasper Therapeutics. ImageneBio is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jasper Therapeutics	N/A	N/A	-$75.80M	-$3.23	N/A
ImageneBio	$800K	79.99	-$45.35M	-$5.79	N/A

In the previous week, Jasper Therapeutics had 6 more articles in the media than ImageneBio. MarketBeat recorded 6 mentions for Jasper Therapeutics and 0 mentions for ImageneBio. Jasper Therapeutics' average media sentiment score of 0.33 beat ImageneBio's score of 0.00 indicating that Jasper Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Jasper Therapeutics	Neutral
ImageneBio	Neutral

79.9% of Jasper Therapeutics shares are owned by institutional investors. Comparatively, 75.0% of ImageneBio shares are owned by institutional investors. 2.3% of Jasper Therapeutics shares are owned by company insiders. Comparatively, 2.2% of ImageneBio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

ImageneBio's return on equity of -38.96% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jasper Therapeutics	N/A	-613.51%	-162.52%
ImageneBio	N/A	-38.96%	-34.60%

Jasper Therapeutics has a beta of 3.07, meaning that its share price is 207% more volatile than the broader market. Comparatively, ImageneBio has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market.

Summary

Jasper Therapeutics beats ImageneBio on 10 of the 15 factors compared between the two stocks.

How does Jasper Therapeutics compare to Prima BioMed?

Jasper Therapeutics (NASDAQ:JSPR) and Prima BioMed (NASDAQ:IMMP) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk.

Jasper Therapeutics has a beta of 3.07, meaning that its share price is 207% more volatile than the broader market. Comparatively, Prima BioMed has a beta of 2.23, meaning that its share price is 123% more volatile than the broader market.

In the previous week, Jasper Therapeutics had 6 more articles in the media than Prima BioMed. MarketBeat recorded 6 mentions for Jasper Therapeutics and 0 mentions for Prima BioMed. Jasper Therapeutics' average media sentiment score of 0.33 beat Prima BioMed's score of 0.00 indicating that Jasper Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Jasper Therapeutics	Neutral
Prima BioMed	Neutral

Jasper Therapeutics presently has a consensus target price of $12.00, suggesting a potential upside of 1,398.13%. Prima BioMed has a consensus target price of $5.50, suggesting a potential upside of 1,251.35%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Jasper Therapeutics is more favorable than Prima BioMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Prima BioMed's return on equity of 0.00% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jasper Therapeutics	N/A	-613.51%	-162.52%
Prima BioMed	N/A	N/A	N/A

Prima BioMed has higher revenue and earnings than Jasper Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jasper Therapeutics	N/A	N/A	-$75.80M	-$3.23	N/A
Prima BioMed	$6.69M	8.97	-$39.78M	N/A	N/A

79.9% of Jasper Therapeutics shares are owned by institutional investors. Comparatively, 2.3% of Prima BioMed shares are owned by institutional investors. 2.3% of Jasper Therapeutics shares are owned by insiders. Comparatively, 3.1% of Prima BioMed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Jasper Therapeutics beats Prima BioMed on 7 of the 12 factors compared between the two stocks.

Get Jasper Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JSPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JSPR vs. The Competition

Export

Metric	Jasper Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$22.46M	$3.65B	$6.80B	$12.43B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-0.25	20.62	27.03	24.19
Price / Sales	N/A	311.45	515.69	92.93
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	5.34	8.13	10.67	6.24
Net Income	-$75.80M	$23.81M	$3.59B	$331.42M
7 Day Performance	10.82%	-1.31%	-0.60%	-1.18%
1 Month Performance	76.82%	2.40%	1.63%	-1.34%
1 Year Performance	-75.05%	44.89%	25.09%	18.73%

Jasper Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JSPR Jasper Therapeutics	3.4414 of 5 stars	$0.80 -1.6%	$12.00 +1,398.1%	-75.6%	$22.46M	N/A	N/A	20	Gap Down
ANVS Annovis Bio	2.4905 of 5 stars	$1.75 -6.2%	$11.67 +568.6%	-36.2%	$64.44M	N/A	N/A	3
CTOR Citius Oncology	1.8336 of 5 stars	$0.70 +2.0%	$6.00 +751.3%	-62.7%	$64.25M	N/A	N/A	N/A	News Coverage Gap Up
EXOZ eXoZymes	0.1244 of 5 stars	$6.37 -8.6%	N/A	-39.5%	$64.19M	$70K	N/A	29	Gap Up
IMA ImageneBio	2.0295 of 5 stars	$6.11 +3.4%	$26.50 +333.7%	-62.4%	$62.97M	$800K	N/A	70	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JSPR) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Jasper Therapeutics (JSPR) Competitors

JSPR vs. ANVS, CTOR, EXOZ, IMA, and IMMP

How does Jasper Therapeutics compare to Annovis Bio?

Summary

How does Jasper Therapeutics compare to Citius Oncology?

Summary

How does Jasper Therapeutics compare to eXoZymes?

Summary

How does Jasper Therapeutics compare to ImageneBio?

Summary

How does Jasper Therapeutics compare to Prima BioMed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JSPR vs. The Competition

Jasper Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Jasper Therapeutics (JSPR) Competitors

JSPR vs. ANVS, CTOR, EXOZ, IMA, and IMMP

How does Jasper Therapeutics compare to Annovis Bio?

Do analysts rate JSPR or ANVS?

Does the media refer more to JSPR or ANVS?

Which has higher earnings & valuation, JSPR or ANVS?

Is JSPR or ANVS more profitable?

Do insiders and institutionals have more ownership in JSPR or ANVS?

Which has more volatility & risk, JSPR or ANVS?

Summary

How does Jasper Therapeutics compare to Citius Oncology?

Do insiders & institutionals hold more shares of CTOR or JSPR?

Which has stronger earnings & valuation, CTOR or JSPR?

Does the media prefer CTOR or JSPR?

Is CTOR or JSPR more profitable?

Do analysts prefer CTOR or JSPR?

Which has more risk & volatility, CTOR or JSPR?

Summary

How does Jasper Therapeutics compare to eXoZymes?

Do analysts recommend EXOZ or JSPR?

Is EXOZ or JSPR more profitable?

Which has higher valuation and earnings, EXOZ or JSPR?

Do institutionals and insiders hold more shares of EXOZ or JSPR?

Which has more risk & volatility, EXOZ or JSPR?

Does the media favor EXOZ or JSPR?

Summary

How does Jasper Therapeutics compare to ImageneBio?

Do analysts recommend JSPR or IMA?

Which has preferable earnings & valuation, JSPR or IMA?

Does the media favor JSPR or IMA?

Do institutionals & insiders hold more shares of JSPR or IMA?

Is JSPR or IMA more profitable?

Which has more volatility & risk, JSPR or IMA?

Summary

How does Jasper Therapeutics compare to Prima BioMed?

Which has more risk and volatility, JSPR or IMMP?

Does the media refer more to JSPR or IMMP?

Do analysts recommend JSPR or IMMP?

Is JSPR or IMMP more profitable?

Which has better valuation & earnings, JSPR or IMMP?

Do insiders & institutionals hold more shares of JSPR or IMMP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JSPR vs. The Competition

Jasper Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools